When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of disease progression compared to a placebo, according to five-year data from a Phase 3 trial. Updated findings from the study, called SOLO-1 (NCT01844986), were presented at the recent 2020 European Society of Medical Oncology virtual congress. Lynparza is an anti-cancer therapy jointly developed by AstraZeneca…
You must be logged in to read/download the full post.
The post Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show appeared first on BioNewsFeeds.